ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 130 filers reported holding ACLARIS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 1.11 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $128,541 | -35.2% | 18,765 | -1.9% | 0.00% | – |
| Q2 2023 | $198,410 | +44.8% | 19,133 | +13.0% | 0.00% | – |
| Q1 2023 | $136,988 | -52.2% | 16,933 | -7.0% | 0.00% | – |
| Q4 2022 | $286,776 | +10.7% | 18,208 | +11.0% | 0.00% | – |
| Q3 2022 | $259,000 | +14.6% | 16,397 | +1.5% | 0.00% | – |
| Q2 2022 | $226,000 | -59.4% | 16,157 | -49.9% | 0.00% | – |
| Q1 2022 | $556,000 | -15.8% | 32,253 | -29.0% | 0.00% | – |
| Q4 2021 | $660,000 | -30.8% | 45,405 | -14.3% | 0.00% | -100.0% |
| Q3 2021 | $954,000 | +22.9% | 52,995 | +19.9% | 0.00% | 0.0% |
| Q2 2021 | $776,000 | – | 44,196 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |